Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
700
Views
9
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

Melita Kenealya Department of Haematology, Cabrini Health, Melbourne, Australia;b Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia;c Melbourne University, Melbourne, AustraliaCorrespondence[email protected]
,
Nigel Pattond Royal Adelaide Hospital, Adelaide, Australia
,
Robin Filshiee St Vincent’s Hospital Melbourne, Australia
,
Andrew Nicolf Greenslopes Private Hospital, Brisbane, Australia
,
Shir-Jing Hog St George Hospital, Sydney, Australia
,
Mark Hertzbergh Department of Haematology, Prince of Wales Hospital and University of New South Wales, Sydney, Australia
,
Tony Millsi Princess Alexandra Hospital, Brisbane, Australia
,
Ian Prosserj Canberra Hospital, Canberra, Australia
,
Emma Linkb Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia
,
Linda Cowanb Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia
,
Diana Zanninok Australasian Leukaemia and Lymphoma Group, Melbourne, Australia
&
John F. Seymourb Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia;c Melbourne University, Melbourne, Australia
 show all
Pages 298-307 | Received 29 Jan 2016, Accepted 10 May 2016, Published online: 07 Jun 2016

References

  • AIHW (Australian Institute of Health and Welfare), AACR (Australasian Association of Cancer Registries). Cancer in Australia: an overview, 2008. Cancer series no. 46. Cat. no. CAN 42.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
  • Prebet T, Gore S, Estemi B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322–3327.
  • Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response; Retrospective analysis of survival after long-term follow-up. Leuk Res. 2015;39:520–524.
  • Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958–965.
  • Raza A, Mehdi M, Mumtaz M, et al. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113:1596–1604.
  • Bennett J, Catovsky D, Daniel M, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
  • Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403–411.
  • Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
  • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.
  • Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol. 2006;24:3895–3903.
  • Gangatharan S, Carney D, Campbell L, et al. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2011;87:186–188.
  • Sekeres M, Othus M, List A, et al. Additional analyses of a randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American intergroup study SWOG S1117. Blood(suppl). 2015;126: Abstract 908.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.